Edaravone

CAS No.: 89-25-8
Molecular Formula: C10H10N2O
Molecular Weight: 174.20
Melting Point: 126-128 °C(lit.)
Boiling Point: 333 °C at 760 mmHg
Flash Point: 155.2 °C
Density: 1.17 g/cm3
Appearance: White or off-white crystal powder
Stability: stable under ordinary conditions. Light sensitive
Purity: ≥99% (HPLC)
Uses: Anti-ischemic and antioxidant

Product Description:
Edaravone is a research reagent, widely used in molecular biology, pharmacology and other scientific aspects. Edaravone is a brain protectant (free radical scavenger). Edaravone can remove free radicals, inhibit lipid peroxidation, thereby inhibiting brain cells, vascular endothelial cells, nerve cells, oxidative damage.
Edaravone is used to help people recover from stroke in Japan, and is used to treat ALS in the US and Japan. It was approved for ALS in the US in 2017 based on a small randomized controlled clinical trial with people who had early-stage ALS in Japan, who were administered the drug for 6 months; it had failed two earlier trials in people with all stages of ALS.
It is given by intravenous infusion.
There is no data on whether it is safe for pregnant women to take, and it is unknown if edaravone is secreted in breast milk.
The label carries a warning about the potential for hypersensitivity reactions to edaravone.
The following adverse effects in at least 2% more people given the drug than were given placebo: bruising, gait disturbances, headache, skin inflammation, eczema, problems breathing, excess sugar in urine, and fungal skin infections.
The mechanism by which edaravone might be effective in ALS is unknown. The drug is known to be an antioxidant, and oxidative stress has been hypothesized to be part of the process that kills neurons in people with ALS.
The half-life of edaravone is 4.5 to 6 hours and the half-lives of its metabolites are 2 to 3 hours. It is metabolized to a sulfate conjugate and a glucuronide conjugate, neither of which are active. It is primarily excreted in urine as the glucuronide conjugate form.